New Meds and tech from D&T Committee: IMCIVREE® (setmelanotide) injection
Prepared by Daniel Mak, MD; Edited by Neha Patel, DO
On March 19, 2026, the FDA approved and expanded indication for IMCIVREE® (setmelanotide), establishing it as the first and only FDA-approved therapy for patients aged 4 years and older with acquired hypothalamic obesity (aHO).1
The FDA approval was supported by data from the global Phase 3 TRANSCEND trial, which evaluated 142 patients with aHO over a 52-week period. Among enrolled participants, 47% were adults, 31% were aged 12 to <18 years, and 23% were 4 to <12 years.1,2
- Primary Endpoint: The study met its primary endpoint demonstrating a statistically significant 18.4% placebo-adjusted reduction in body mass index (BMI) after 52 weeks. Patients treated with setmelanotide achieved a mean 15.8% BMI reduction compared with a +2.6% increase in the placebo group.2 Overall, 75.79% of treated patients achieved >5% BMI reduction (vs. 9.73% placebo) and 60.99% achieved >10% BMI reduction (vs. 4.69% placebo).2
Among patients 12 years and older, setmelanotide also produced a statistically significant reduction in daily maximal hunger scores compared withplacebo.2
Safety and Tolerability: Generally, setmelanotide was well tolerated during the Phase 3 trial.
- Common Adverse Events: The most frequent side effects (affecting ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.2
Specific Warnings for Acquired HO: The FDA label includes specific warnings for patients with aHO to monitor for acute adrenal insufficiency (reported in 5% of treated patients with secondary adrenal insufficiency) and sodium imbalances (hyponatremia and hypernatremia) in patients with concomitant AVP deficiency (formerly known as central diabetes insipidus).2
Dosing: For aHO, the starting dose is lower than for other indications – 0.5 mg subcutaneously once daily for 2 weeks, followed by age- and weight-based titration.3
Initiation: Treatment initiation is consistent with other approved indications. The IMCIVREE® Prescription Start Form has been updated accordingly.3
References: